← Back to Clinical Trials
Recruiting NCT05445544

NCT05445544 A Multicenter Cohort Study on Maternal and Infant Microecology and New Targets for Pre-eclampsia Screening in China

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05445544
Status Recruiting
Phase
Sponsor Zhujiang Hospital
Condition Preeclampsia
Study Type OBSERVATIONAL
Enrollment 10,000 participants
Start Date 2022-10-19
Primary Completion 2027-12-31

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Observational studies, The diagnosis was preeclampsia

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 10,000 participants in total. It began in 2022-10-19 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

major objective This multicenter, prospective cohort study aims at evaluating the predictive value of microbiome ,proteomics and serum markers in preeclampsia. secondary objective to evaluate the value of microbiome,proteomics and serum markers in assessing pregnancy outcome (complications during pregnancy and delivery, delivery) and neonatal prognosis.

Eligibility Criteria

Inclusion Criteria: * Aged \>=18 years; * Pregnancy woman; * With a singleton pregnancy; * Volunteer and receive regular antenatal examinations in the research centers; * Volunteer to sign a written informed consent. Exclusion Criteria: * Concurrent with hypertension, diabetes, liver and kidney diseases, hematonosis and other serious diseases of pre-pregnancy women, including patients requiring long-term medication for primary diseases; * With history of preeclampsia; * Tumor patients concurrent with serious infection requiring long-term drug treatment; * Pregnant women conceiving through in vitro fertilization; * Multiple pregnancies; * Patients with clear indications of medical pregnancy termination during early pregnancy; * Any medical or non-medical conditions deemed inappropriate for study participation according to the investigator.

Contact & Investigator

Central Contact

Sihua Qin

✉ 274896180@qq.com

📞 15622136950

Principal Investigator

hongwei zhou

STUDY CHAIR

Zhujiang Hospital

Frequently Asked Questions

Who can join the NCT05445544 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Preeclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05445544 currently recruiting?

Yes, NCT05445544 is actively recruiting participants. Contact the research team at 274896180@qq.com for enrollment information.

Where is the NCT05445544 trial being conducted?

This trial is being conducted at Guangzhou, China, Guangzhou, China.

Who is sponsoring the NCT05445544 clinical trial?

NCT05445544 is sponsored by Zhujiang Hospital. The principal investigator is hongwei zhou at Zhujiang Hospital. The trial plans to enroll 10,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology